Infectious Diseases: Safety Concerns with Fluoroquinolones
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Objective: To review the chemistry, pharmacology, and safety of fluoroquinolones. Data Sources: A MEDLINE search (1966–July 2007) was conducted using the key words fluoroquinolones or quinolones with safety, adverse effects, hypoglycemia. hyperglycemia, dysglycemia. QTc prolongation, torsades, seizures, phototoxicity, tendon rupture, Clostridium difficile, and pseudomembranous colitis for articles published in the English language. Study Selection and Data Extraction: Medicinal chemistry, in vitro, animal, and human trials were reviewed for information on the chemistry, pharmacology, and safety of each fluoroquinolone. Clinical trials were reviewed and included to compare the safety of systemic fluoroquinolones on the market. Literature on the pathology of serious adverse effects was also reviewed. Data Synthesis: Gatifloxacin has been shown to increase the risk of hospitalization for dysglycemia in patients with and without diabetes. Hyperglycemia may occur with any fluoroquinolone, especially if not properly dose adjusted. Hypoglycemia may occur with any fluoroquinolone and has a higher frequency in patients receiving concomitant oral hypoglycemic drugs or insulin. Use of any fluoroquinolone should be avoided in patients with risk factors for QTc interval prolongation or tendinopathy. All fluoroquinolones should be used with caution in patients with a history of seizure disorders and may cause phototoxicity or C. dífficile–associated diarrhea (CDAD). Conclusions: Clinicians should be aware of possible alterations in blood glucose, QTc interval prolongation, seizures, phototoxicity, tendinopathy, or CDAD with the use of any fluoroquinolone, especially in patients with other risk factors for these conditions. Clinicians should closely monitor for these adverse effects and appropriately adjust doses to minimize these risks. To provide safe treatment for patients needing antibiotic therapy, an assessment of the risk–benefit ratio may be warranted in the decision to use a fluoroquinolone
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug-induced prolongation of the QT interval
Roden, D. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032426 · Cited by 1,965
Outpatient gatifloxacin therapy and dysglycemia in older adults.
Park-Wyllie, L. Y., Juurlink, D. N., Kopp, A., Shah, B. R., Stukel, T. A., Stumpo, C., Dresser, L., Low, D. E., & Mamdani, M. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055191 · Cited by 367
Cited by
Thwaites, G., Fisher, M., Hemingway, C., Scott, G., Solomon, T., & Innes, J. (2009) · Journal of Infection · doi:10.1016/j.jinf.2009.06.011 · Cited by 666
Tuberculous meningitis: more questions, still too few answers
Thwaites, G. E., van Toorn, R., & Schoeman, J. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70168-6 · Cited by 482
Photocontrol of Antibacterial Activity: Shifting from UV to Red Light Activation
Wegener, M., Hansen, M. J., Driessen, A. J. M., Szymanski, W., & Feringa, B. L. (2017) · Journal of the American Chemical Society · doi:10.1021/jacs.7b09281 · Cited by 324
Drug-Induced Photosensitivity—An Update: Culprit Drugs, Prevention and Management
Blakely, K. M., Drucker, A. M., & Rosen, C. F. (2019) · Drug Safety · doi:10.1007/s40264-019-00806-5 · Cited by 122
Bito, M., Tomita, T., Komori, M., Taogoshi, T., Kimura, Y., & Kihira, K. (2013) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b12-00425 · Cited by 20
Metadata
- Authors
- Mehlhorn, A. J., & Brown, D. A.
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2007-11
- Volume
- 41
- Issue
- 11
- Pages
- 1859-1866
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2105742053
- Cited by
- 204
- References
- 2
- FWCI
- 25.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.